GlassScriptPhysician profile
Bruce E Wiita
NPI 1013959741
$2,643.88
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $477 · 2021: $594 · 2022: $635 · 2023: $357 · 2024: $35.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $393.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $392.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $530.20 | 2019-2023 | Xtandi |
| Janssen Biotech, INC. | $444.65 | 2019-2023 | Erleada |
| Endo Pharmaceuticals INC. | $441.53 | 2019-2024 | Aveed, Xiaflex, Edex |
| Pfizer INC. | $276.42 | 2019-2023 | |
| Abbvie INC. | $235.94 | 2019-2024 | Botox |
| Coloplast Corp | $217.25 | 2019-2023 | Speedicath |
| Allergan, INC. | $123.51 | 2019-2022 | |
| Tolmar Pharmaceuticals, INC. | $106.40 | 2019-2022 | |
| Tolmar, INC. | $45.59 | 2023 | |
| Boston Scientific Corporation | $43.77 | 2019-2020 | |
| Myovant Sciences INC. | $33.61 | 2021 | |
| Convatec INC. | $32.39 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.86 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.88 | 2023 | |
| Merck Sharp & Dohme LLC | $17.41 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $16.56 | 2022 | |
| Olympus America INC. | $15.31 | 2019 | |
| Laborie Medical Technologies Corp. | $13.60 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Wiita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.